Trial Profile

A Randomized, Double Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 Tablets in Adult Patients With Alopecia Areata

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivarmacitinib (Primary)
Indications Alopecia areata
Focus Therapeutic Use
Sponsors Reistone Biopharma

Most Recent Events

03 Apr 2023 Results assessing efficacy and safety of ivarmacitinib in adult with Alopecia Areata published in the Journal of the American Academy of Dermatology
24 Aug 2021 Results presented in a Reistone Biopharma Media Release.
24 Aug 2021 According to a Reistone Biopharma media release, Primary endpoint (Percentage change from baseline in Severity of Alopecia Tool (SALT) score) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com